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The Human Chorionic Gonadotropin Derivate
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Summary: The extent of the systemic inflammatory response following infectious or noninfectious insults is related
to impaired patient outcome. Pregnancy is associated with immunotolerance and an increased glomerular filtration
rate. EA-230 is a newly developed synthetic linear tetrapeptide derived from the “pregnancy hormone” human chori-
onic gonadotropin. In this review, we describe the immunomodulatory and renoprotective properties of EA-230 in
preclinical animal models, phase 1 studies in humans and phase 2a studies performed during human experimental
endotoxemia. In addition, details pertaining to the design of a recently completed phase 2b study in 180 patients
who underwent cardiac surgery to investigate the safety and immunomodulatory and renoprotective properties of
EA-230 are discussed.
Semin Nephrol 39:496−504  2019 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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S
ystemic activation of the immune system in
response to invading pathogens and/or tissue
injury is essential for the clearance of pathogens
and initiation of tissue repair mechanisms. However,
several infectious (eg, sepsis) and noninfectious condi-
tions (eg, trauma and major surgical interventions) may
cause an inappropriate systemic activation of the
immune system (eg, too pronounced or protracted).1,2
This dysregulated inflammatory response often results in
tissue damage, failure of one or more organ systems, and
high mortality.3,4 An example is the development of
acute kidney injury, one of the first and most frequent
manifestations of inflammation-induced organ failure,
which occurs in over half of the critically ill patients and
in up to 30% of patients undergoing elective cardiac
surgery.5-8 Furthermore, acute kidney injury has been
associated with impaired clinical outcome; even a mini-
mal increase in serum creatinine has been shown to cor-
relate with impaired survival in patients undergoing
elective cardiac surgery.6,9
Although the consequences of a dysregulated immune
response have a large impact on patients, current thera-
peutic strategies are still confined to supportive treat-
ment. To date, all immunomodulatory interventions have
failed to demonstrate clear beneficial effects in terms of
preventing organ injury.10-12 For example, large studies
investigating the use of high dose corticosteroids
revealed no improvements in overall outcome of patients
with systemic inflammation following cardiac sur-
gery.13,14 However, nonspecific anti-inflammatory
effects and/or the broad spectrum of adverse reactions
may have contributed to the absence of overall beneficial
effects. Therefore, novel pharmaceutical strategies that
aim to more safely and more specifically target the dys-
regulated inflammatory response to prevent organ failure
are highly warranted.
The unique immunologic adaptation of the maternal
immune system during pregnancy has inspired research
into new immunomodulatory strategies. In pregnancy, a
remarkable symbiosis of two major histocompatibility
complex incompatible individuals enables the semi-alloge-
neic fetus to be tolerated by the maternal immune system,
whereas the ability to combat invading pathogens remains
unaffected.15 Strikingly, pregnancy-related rearrangements
of the maternal immune system are associated with
improvement of several autoimmune diseases, including
rheumatoid arthritis, psoriasis, and multiple sclerosis, while
relapse of these diseases usually occurs following deliv-
ery.16-19 Nevertheless, the immune system of pregnant
women is fully capable to combat pathogens. As such, the
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pregnancy-induced immunologic adaptation is character-
ized by suppression of detrimental (auto-)immunologic
processes to mother and fetus, whereas beneficial immune
processes such as host defence remain unaffected. An
immunomodulatory pharmacological compound that could
mimic these favorable features might be of benefit for
patients suffering from overzealous systemic inflammation.
Several possible underlying mechanisms via which
the maternal immune system adapts during pregnancy
have been postulated and investigated. Although there is
no clear consensus on this topic, changes in the hormonal
milieu appear to play a central role.20 Of particular inter-
est is the release of the “pregnancy hormone” human
chorionic gonadotropin (hCG). This hormone is pro-
duced throughout pregnancy, already present at a very
early gestational stage, and may increase up to 50.000-
fold at the end of the first trimester. Several studies have
reported hCG-mediated immunomodulatory effects.21-26
An important role in these effects are liked to immuno-
logically active oligopeptides originating from the
b-loop of hCG, which are abundantly present throughout
pregnancy.27 As such, various b-hCG-derived oligopep-
tides have been studied, and were demonstrated to exert
immunomodulatory effects, limit organ failure, and
decrease mortality in several animal models of systemic
inflammation.27-33 Of the assessed oligopeptides, the
linear tetrapeptide Alanine-Glutamine-Glycine-Valine
(later named EA-230) showed the most promising
effects. EA-230 strongly attenuated inflammation and
substantially reduced organ failure and mortality in mod-
els of hemorrhagic28 and endotoxemia-induced shock.29
Furthermore, treatment with EA-230 exerted kidney-pro-
tective effects in ischemia-reperfusion (IR) and kidney
transplant models.31,34 These findings may be related to
the fact that pregnancy profoundly impacts renal func-
tion by increasing renal flow and the glomerular filtration
rate (GFR).35
This review describes the development of EA-230,
ranging from experimental dose finding, pharmacokinetic
profiling and efficacy studies in animals, to the clinical
development of EA-230 with first-in-man and first-in-
patient trials. These studies in healthy volunteers and
patients include dose finding, pharmacokinetics, safety
and tolerability, and efficacy assessments.
PRECLINICAL PHARMACOKINETIC STUDIES
Several animal studies have evaluated the pharmacoki-
netics of EA-230, of which a detailed description is
described in supplementary material elsewhere.36
Briefly, the distribution and metabolism of EA-230 was
examined following a single intravenous (IV) injection
of 50 mg/kg radiolabeled EA-230 (Ala-Gln-[1-14C]Gly-
Val) in mice. EA-230 was shown to be rapidly removed
from the blood, as metabolite profiles in blood plasma
and urine obtained 10 minutes after administration
revealed no intact EA-230 peptides. This indicates that
systemic EA-230 clearance is high (eg, exceeding liver
blood flow). In rats, IV administration of EA-230 (50,
100, or 200 mg/kg/day) for 5 days, again revealed rapid
(within minutes) elimination of EA-230. The volume of
distribution of EA-230 was high (range, 2-50 L/g), sys-
temic clearance was swift (range, 14-43 L/g/h), and as a
consequence, elimination half-life was short (<30
minutes). Furthermore there was no evidence of accumu-
lation on repeated dosing. Finally, a 2-week repeated
dose toxicity study with EA-230 administrations up to
200 mg/kg/day was performed in dogs. Besides the max-
imum tolerated dose of 200mg/kg/day that was estab-
lished, a pharmacokinetic profile similarly to the studies
in mice and rats was observed: rapid elimination of EA-
230 from the circulation, a large volume of distribution
and a short elimination half-live (< 50 minutes). Further-
more, more than dose-proportional increases of plasma
concentrations over time were observed.
PRECLINICAL EFFICACY STUDIES
EA-230 has been evaluated in multiple animal models of
renal injury. Among various oligopeptides tested in a
murine model of renal IR damage (25 minutes of renal
pedicle clamping), EA-230 (5 mg/kg, administered 1
minute before clamping and 1 minute before reperfu-
sion) showed high efficacy in preservation of renal func-
tion and prevention of mortality. No animals died within
72 hours after clamping versus 50% mortality in the con-
trol group.31 Improved survival and renal preservation
were confirmed in subsequent experiments using ascend-
ing dosages of EA-230 (0.3-30 mg/kg).31 Furthermore,
IR-induced systemic inflammation was significantly
attenuated, which was reflected by attenuation of circu-
lating levels of cytokines interleukin 6 (IL-6), interleukin
10 (IL-10), interferon gamma, and tumor necrosis factor
alpha (TNF-a), reduced neutrophil influx into renal tis-
sue, and a decreased expression of the leukocyte adhe-
sion molecule E-selectin.31 Notably, EA-230 improved
IR-related survival even when administered late: initiat-
ing therapy (30 mg/kg EA-230 twice daily for 4 consecu-
tive days) at 24 hours after 35 minutes of renal clamping,
resulted in 70% survival after 3 days versus no survival
in the control group. The deterioration of renal function
was prevented and the increase in serum concentrations
of the cytokine IL-6 and monocyte chemoattractant pro-
tein-1 was attenuated. A more elaborate renal IR study
(35 minutes of pedicle clamping) using ascending dos-
ages of 20-50 mg/kg twice daily for 4 consecutive days
confirmed the previously observed improved survival
after treatment with EA-230. Interestingly, this study
also showed EA-230 to mitigate acute tubular injury, to
enhance tubular epithelial cell proliferation, and to atten-
uate the upregulation of markers related to postischemic
fibrosis.34 EA-230 improved renal blood flow and the
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GFR at 28 hours after IR damage.34 A different murine
model of renal injury was used in which an allogeneic
kidney was transplanted, recipients treated with EA-230
(50 mg/kg) showed markedly improved survival and
preservation of renal function, accompanied by enhanced
allograft survival and a decrease in acute tubular necrosis
compared with the control group.34
Parallel to these IR studies, preclinical work has
focused on the immunomodulatory properties of EA-230
in models of systemic inflammation. In a rat model, 60
minutes of hemorrhagic shock was used to induce pro-
nounced systemic inflammation with subsequent hepatic
failure.28 Rats treated with a single bolus administration
of EA-230 (5mg/kg 30 minutes after the initiation of
shock) displayed an attenuated systemic inflammatory
response compared with saline-treated animals. At
organ level, EA-230 administration resulted in reduced
hepatic mRNA expression of TNF-a, IL-6, and E-
selectin.28 Furthermore, a nonsignificant trend toward
preservation of hepatic function and prevention of neu-
trophil infiltration into the liver was observed.28 Like-
wise, in mice infected with Listeria Monocytogenes,
EA-230 (50 mg/kg every 24 hours for 3 days) attenu-
ated systemic cytokine levels and reduced tissue influx
of neutrophils.32 Immunomodulatory effects of EA-230
have also been explored in murine models of sepsis.
These include administration of endotoxin (lipopoly-
saccharide [LPS]), a specific Toll-like receptor-4
(TLR-4) ligand. In this model, treatment with EA-230
(both at 2 and 24 hours post-LPS administration)
resulted in a significant decrease in sickness scores
and attenuation of splenocyte proliferation compared
with placebo-treated animals.29 Furthermore, EA-230
completely prevented endotoxemia-induced mortality
84 hours after LPS administration (100% versus 0%
survival).29 As LPS models solely induce TLR-4-medi-
ated inflammation, cecal ligation and puncture (CLP)
model has been used to examine the effects of EA-230
on polymicrobial sepsis. CLP more accurately reflects
polymicrobial sepsis and is therefore considered
the gold standard animal sepsis model. After CLP,
mice treated with escalating dosages of EA-230
(5-50 mg/kg, 4 and 16 hours after CLP and thereafter
daily over 4 days) showed improved survival (50% in
EA-230 50 mg/kg treated animals versus 0% in placebo
animals), attenuated cytokine responses, and reduced
influx of leukocytes into the peritoneal space. Further-
more, renal function was preserved in the EA-230 group,
illustrated by an attenuated increase of serum creatinine
levels and a less pronounced decline in GFR and renal
blood flow. Of interest and relevant to the clinical situa-
tion: the latter results were confirmed in experiments in
which EA-230 was administered late and only twice
(4 and 16 hours following CLP induction).
Taken together, EA-230 has been demonstrated to
attenuate the release of systemic inflammatory
mediators, to reduce tissue leukocyte infiltration, and to
mitigate organ damage (particularly renal failure) in
various animal models of renal injury, as well as during
sterile and infectious systemic inflammation. Because of
these promising results, EA-230 has been advanced into
clinical development.
CLINICAL STUDIES
Several human studies in both healthy subjects and
patients have been conducted. These include three phase
1 studies in healthy volunteers to investigate safety, tol-
erability and pharmacokinetics of EA-230. To investi-
gate the immunomodulatory potential in humans, two
phase 2a studies were performed in healthy volunteers
undergoing experimental human endotoxemia, a stan-
dardized, controlled and reproducible model of systemic
inflammation. Finally, a phase 2b study on safety, tolera-
bility and efficacy of EA-230 in patients undergoing car-
diac surgery is currently being conducted. These studies
are discussed in the current paragraph and an overview
of all clinical studies performed to date is provided in
Table 1.
Phase 1 Studies
The first-in-man studies to investigate the pharmacoki-
netics, safety and tolerability of EA-230 were conducted
using several dosing schemes: escalating single and mul-
tiple dosages and escalating single continuous dosages.36
A single dosage study was conducted in 32 healthy
male volunteers. Subjects were assigned to one of four
dosage groups: 1, 3, 10, and 30 mg/kg. Each group con-
sisted of 8 subjects (EA-230: n = 6, placebo: n = 2),
randomized in a double-blind fashion. Subjects were
hospitalized for 24 hours and followed-up for a period of
14 days in which vitals signs were monitored and blood
samples were taken regularly.
A 3-day multiple dosage study was conducted in 24
healthy male volunteers using escalating dosage groups
of 10, 20, and 30 mg/kg. Each dosage group consisted of
8 subjects (EA-230: n = 6, placebo: n = 2), randomly
assigned in a double-blinded fashion. 3 boluses were
administered in 10 minutes with intervals of 8 hours for
3 consecutive days (9 dosages in total). Subjects were
hospitalized and monitored until 12 hours after the last
dosage administration and returned after 14 days for fol-
low-up.
Finally, a continuous dosage study was conducted in
24 healthy male and female subjects who were assigned
to one of three dosage groups: 15, 45, or 90 mg/kg with
an IV infusion duration of 2 hours. Subjects were ran-
domly assigned to receive EA-230 (n = 6) or placebo
(n = 2) in a double-blinded fashion. Subjects were moni-
tored until 6 hours after cessation of study drug adminis-
tration and followed-up for a period of 14 days.
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In the aforedescribed first-in-man studies, the preclin-
ical pharmacokinetic profile of EA-230 was reconfirmed.
The pharmacokinetical profile of EA-230 in humans is
characterized by a large volume of distribution, very
rapid clearance, and a short half-life of less than 15
minutes. This very rapid plasma clearance exceeds both
the renal and portal flow, implying proteolysis, hydroly-
sis, tissue/protein binding, and/or cellular uptake of the
peptide. Furthermore, conform earlier preclinical work,
subjects in the highest dosage group showed lasma con-
centration higher than proportional to the administered
dosage. This may suggest dose-dependent metabolism,
elimination, and/or a shift in distribution.
Importantly, no safety issues emerged across all dos-
age groups as no serious adverse events (SAEs) were
reported. Overall, all AEs were transient and mild and
no dose-dependent increase in the number or intensity of
AEs was observed. Moreover as 50% of the AEs were
observed in placebo-treated subjects, the likelihood that
AEs were related to the compound was therefore consid-
ered low. Notably, in the continuous infusion study, with
accordingly the highest plasma concentrations and the
longest exposure, no possibly related AEs were reported.
No effects of EA-230 on vital parameters were found.
In conclusion, all available data on pharmacokinetics,
safety and tolerability in a total of 80 healthy volunteers
show a pharmacokinetic profile of EA-230 that is in line
with the results of preclinical studies; a short half life,
large volume of distribution, no accumulation after mul-
tiple dosing and a more-than-proportional increase in
plasma concentration. Furthermore these phase 1 studies
reveal EA-230 to be well tolerated without the occurence
of any safety issues.
Phase 2a Experimental Human Endotoxemia
Studies
The encouraging results from phase 1 studies prompted
the design of studies to assess immunomodulatory
effects of EA-230 in humans. These studies used experi-
mental human endotoxemia as a model for systemic
inflammation. In this model, endotoxemia is induced in
healthy volunteers by administering purified Escherichia
coli-derived LPS, which elicits a systemic inflammatory
response. LPS activates the immune system only through
ligation of TLR-4, which is in contrast to the plethora of
pathways that are activated in patients with systemic
inflammation related conditions such as sepsis. However,
this temporary inflammatory response captures several
hallmarks of systemic inflammation in patients. The
LPS-induced inflammatory response shows considerable
overlap in terms of cytokine production and leukocyte
activation. Moreover, LPS administration induces com-
parable but less pronounced clinical symptoms such as
an increase in heart rate, a decrease in blood pressure, an
increase in body temperature and the development of
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flu-like symptoms.37 This LPS induced inflammatory
response is short-lived, relatively mild, not associated
with clinically relevant organ dysfunction and well-toler-
ated by numerous subjects that underwent experimental
human endotoxemia worldwide.37 Furthermore, these
endotoxemia studies can be conducted in a highly stan-
dardized manner, using a homogenous population that
can be intensively monitored. Experimental human
endotoxemia therefore represents a very suitable model
to assess the immunmodulaory behavior of a drug such
as EA-230.
In the first study that evaluated safety and the immu-
nomodulatory effects of EA-230 during human endotox-
emia, 12 subjects were enrolled who all received an IV
bolus administration of 4 ng/kg LPS. After randomiza-
tion, eight subjects were administered 10 mg/kg EA-230
(IV bolus), whereas four received placebo. Primarily,
administration of EA-230 was well tolerated in this study
without any safety concerns.
Furthermore, EA-230 significantly attenuated the
LPS-induced increase in plasma concentrations of proin-
flammatory cytokines IL-6 and IL-8 levels over time
compared with the placebo group (P = .04 and P = .004,
respectively, Fig. 1), with a decrease in area under the
time-concentration curve of 46% for IL-6 and 36% for
IL-8. Also, a significantly attenuated increase in body
temperature was observed in the EA-230 group 4 hours
after LPS administration (temperature change [minimal-
maximal] in the EA-230 group of +0.6˚C [0-2] versus
+1.6˚C [1-2] in the placebo group, P = .02). There were
no between-group differences in total leukocyte counts
or subsets over time. The observerd pharmacokinetic
profile of EA-230 was similar to those observed in phase
1 studies.
In a slightly different setup, the effect of continuous
administration of EA-230 on LPS-induced systemic
inflammation was investigated in 36 healthy volun-
teers.38 Briefly, in this study EA-230 was administered
continuously considering its short half-life. Subjects
were randomly assigned to one of three dosage groups:
15, 45, or 90 mg/kg/h. In each dosage group, eight sub-
jects received EA-230 IV and four subjects received pla-
cebo. LPS administration (IV bolus of 2 ng/kg) was
directly followed by continuous study drug infusion for a
period of 2 hours. The primary endpoint was safety and
tolerability, whereas the primary efficacy endpoint was
EA-230-induced modulation of the inflammatory
response. In total, 19 mild and transient AEs were
reported that were equally distributed over the treatment
and placebo groups. AEs were assessed as having no or
an unlikely relation with the study drug. No SAEs were
reported. The highest dosage of EA-230 (90mg/kg/h)
exerted significant effects on plasma levels of several
proinflammatory cytokines and chemokines, reducing
the area under the time-concentration curve of IL-6 by
48%, IL-8 by 28%, and monocyte chemoattractant pro-
tein-1 by 28% (an overview of cytokine data is provided
in Fig. 2). Although levels of proinflammatory cytokines
were attenuated in subjects who received EA-230,
plasma concentrations of the anti-inflammatory cytokine
IL-10 were not significantly affected. The LPS-induced
increase in body temperature was significantly less pro-
nounced in the EA-230 90mg/kg/h group compared with
placebo (maximum increase of 1.3 § 0.2˚C versus 1.8 §
0.1˚C in placebo-treated subjects, P = .003). Also flu-like
symptoms (headache, nausea, shivering, muscle and
back pain, and vomiting scored per item on a 0-5 Likert
scale) were significantly less pronounced in this group
(maximum score of 4.0 § 1.2 points versus 7.4 § 1.0
points in placebo-treated subjects, P < .0001). The LPS-
induced increase in leukocyte counts was enhanced in
the EA-230 group compared with the placebo group,
Figure 1. Plasma levels of cytokines during experimental human endotoxemia. (A) IL-6 and (B) IL-8. Data are repre-
sented as means with standard error of the mean. N = 8 in the EA-230 group, n = 4 in the placebo group. Lipopolysac-
charide and study drug or placebo were infused on T = 0. P values between groups were calculated using repeated
measures 2-way analysis of variance (interaction term). Abbreviation: IL, interleukin.
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largely accounted for by higher numbers of neutrophils
and monocytes. Interestingly, pharmacokinetic analysis
showed that plasma concentrations were approximately
two-fold higher compared with the phase 1 study using
the same dosages conducted in the same institute with
identical analysis methods. These data suggest that sys-
temic inflammation may affect the volume of distribu-
tion and/or the clearance of EA-230, for which the
underlying mechanisms remain elusive.
Human experimental endotoxemia studies showed
EA-230 to be safe and well-tolerated under inflammatory
conditions in a total of 48 healthy volunteers. The immu-
nomodulatory effects of EA-230 were confirmed in these
studies, illustrated by attenuation of circulating plasma
levels of proinflammatory cytokines and chemokines a
significantly less pronounced increase in body tempera-
ture, and less development of flu-like symptoms in
EA-230 treated subject compared with placebo.
Furthermore, pharmacokinetic results were similar to the
phase 1 studies, except for the finding that plasma con-
centrations of EA-230 were approximately two fold
higher under LPS induced inflammatory conditions.
Phase 2b Study
The next step in the clinical development of EA-230 is
represented by a currently ongoing patient trial, of which
the design is described in detail elsewhere.39 Briefly, this
Figure 2. Area under the time-concentration curve of both phase 2a experimental human endotoxemia studies.
Depicted is the mean § standard error of the mean and the difference in area under the time-concentration curve as a
percentage. *Tested statistically significant using repeated measures 2-way analysis of variance (interaction term).
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study is performed in patients undergoing elective coro-
nary artery bypass grafting with or without valve surgery
and aims to investigate both safety and efficacy in a
large and relatively homogeneous group of patients suf-
fering from systemic inflammation. There are several
charesteristics to a cardiac surgical procedure that makes
it eligible to study the immunomodulatory effects
of EA-230. First, cardiac surgery is known to elicit a
systemic inflammatory response.40,41 A combination of
surgical procedures contribute to this inflammatory
response, such as sternotomy, the use of a cardiopulmo-
nary bypass, IR damage following aortic clamping and
endotoxemia owing to increased gut permeability.40-42
This systemic inflammatory response is predictable and
interpatient differences are relatively limited. Second,
these patients have a considerable likelihood of develop-
ing renal injury due to multiple causes, including hemo-
dynamic changes, direct IR injury to the kidneys
following aortic cross clamping, systemic inflammation,
and hypoxia.5 This is of interest in view of the previously
described putative renal protective effects of EA-230.
Finally, as this cardiac surgical procedures are elective
and highly standardized, this group of patients conveys
the opportunity to uniformly time the administration of
the investigational compound relative to the inflamma-
tory and kidney-damaging insults.
In the study, 180 patients were randomized to continu-
ous IV administration of EA-230 (90mg/kg/h) or placebo
(1:1 ratio) in a double-blinded fashion. Infusion of EA-
230 started at surgical incision and stopped after cessation
of the cardiopulmonary bypass. To assess safety and cyto-
kine responses, frequent blood samples were collected
untill the morning after surgery. Patients were followed-
up for 90 days after surfery to monitor for adverese
events. The study is currently completed and data analysis
is in progress (Clinicaltrials.gov; NCT03145220; https://
clinicaltrials.gov/ct2/show/NCT03145220). The primary
objectives of this first-in-patient study are to study safety
and tolerability of EA-230 in patients, and to demonstrate
the immunomodulatory effects of EA-230. Safety and tol-
erability are the primary focus of this study, defined as the
incidence of (S)AEs and changes in vital signs and routine
laboratory parameters between active and placebo treat-
ment. The primary efficacy endpoint is IL-6 plasma con-
centration over time. The key-secondary endpoint is the
effect of EA-230 on renal function (the “true GFR” mea-
sured by iohexol plasma clearance43). Additional efficacy
endpoints include the effects of EA-230 on plasma con-
centrations of other cytokines and chemokines (among
which are IL-8, IL-10, and TNF-a), hemodynamic data,
and several tubular injury markers (including urinary neu-
trophil gelatinase-associated lipocalin, L-type fatty acid-
binding protein, N-acetyl-b-D-glucosaminidase, and inter-
leukin-18). Several clinical endpoints are included as
well, such as effects of EA-230 on vasopressor require-
ment, fluid balance, changes in sequential organ failure
assessment score, intensive care unit length of stay,
hospital length of stay, and mortality. The study employed
an adaptive design: after enrolment of 90 patients a recal-
culation of the sample size using the obtained IL-6 data
were performed.
Several potential pitfalls related to this phase 2b trial
may be of importance. First, the inflammatory response
observed following cardiac surgery is not the same as that
elicited by IV LPS administration due to profound differ-
ences between the inciting events. This discrepancy is for
instance reflected in plasma cytokine concentrations: fol-
lowing coronary artery bypass grafting, cytokine concen-
trations will reach peak concentrations hours later, will be
less pronounced, and will remain elevated for a longer
period of time compared with the cytokine concentrations
following LPS administration.44 This may complicate
optimal timing of the intervention as EA-230 infusion
will most probably be stopped prior to the expected peak
inflammatory response in patients undergoing cardiac sur-
gery, whereas EA-230 infusion was ongoing during the
peak inflammatory response following LPS administra-
tion. Furthermore, EA-230 has an extraordinary large vol-
ume of distribution and is rapidly eliminated from the
circulation. This may result in a very short duration of
action. Combined with the fact that the mode of action of
EA-230 remains largely elusive, this may hamper accu-
rate timing and duration of therapy. In this respect, it is
noteworthy that in preclinical studies, EA-230 has shown
comparable efficacy on both early (just prior to or shortly
after the inflammatory insult) and delayed administration
(up to 24 hours after the inflammatory insult).29,32,34
The results of the phase 2b patient study are expected
in 2019. A favorable outcome of the trial may instigate
the design of a large multicenter phase 3 trial. It would
also pave the way for exploration of EA-230s applicabil-
ity for other conditions in which systemic inflammation
and renal damage play a central role, such as in patients
with sepsis and trauma.
CONCLUSIONS
A too pronounced or protracted systemic inflammatory
response may induce tissue damage and failure of
organs, of which the kidneys are most likely affected.
This phenomenon is observed in noninfectious as well as
infectious causes of systemic inflammation. To date,
immunomodulatory therapies have not led to improved
outcome, and supportive treatment is therefore the only
strategy in current clinical use. The b-hCG-derived tetra-
peptide EA-230 has been shown to attenuate systemic
inflammation, preserve renal function, and increase sur-
vival in various preclinical studies. Furthermore, EA-
230 was found to be safe and well-tolerated in five inde-
pendent human studies using different dosages and
administration strategies. EA-230s immunomodulatory
effects were subsequently confirmed in humans in two
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experimental human endotoxemia studies. The results of
a large double blind placebo-controlled randomized
phase 2b trial in patients undergoing cardiac surgery are
anticipated.
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